Perceptic, a biotechnology startup founded by former artificial intelligence executives from Palantir Technologies, has raised $12 million in seed funding to accelerate the development of its AI-powered drug discovery platform. The funding round marks a significant milestone for the young company as it seeks to transform how new medicines are identified and developed.
The startup aims to use advanced artificial intelligence models to automate key stages of the drug discovery process, helping researchers analyze vast amounts of biological and chemical data more efficiently. By reducing the time required to identify promising drug candidates, Perceptic hopes to speed up the development of treatments for a range of diseases.
Drug discovery has traditionally been a lengthy and expensive process, often taking years of research and billions of dollars in investment before a new therapy reaches patients. AI-driven platforms have attracted growing interest from pharmaceutical companies and investors because they have the potential to shorten development timelines and improve the success rate of research programs.
Perceptic’s founders bring experience in applying artificial intelligence to complex data challenges, having previously worked on large-scale AI systems and analytics projects. The company plans to leverage that expertise to build tools capable of identifying patterns in biological data that may be difficult for traditional methods to detect.
The newly raised capital will be used to expand the company’s engineering and scientific teams, further develop its technology platform, and establish partnerships with pharmaceutical and biotechnology organizations. Perceptic also plans to invest in computational infrastructure needed to support increasingly sophisticated AI models.
Investors backing the startup cited the growing convergence of artificial intelligence and life sciences as a major opportunity. The use of AI in healthcare research has gained momentum in recent years, with companies exploring machine learning techniques to discover drug targets, predict molecular behavior, and optimize clinical development strategies.
Industry analysts believe AI could play an increasingly important role in reducing the cost and complexity of bringing new medicines to market. While challenges remain, advances in computing power and data availability have fueled optimism about the technology’s potential impact on the pharmaceutical sector.
With fresh funding and an experienced leadership team, Perceptic is positioning itself among a new generation of startups seeking to reshape drug discovery through artificial intelligence. The company hopes its platform can help researchers identify promising treatments faster and ultimately accelerate the delivery of new therapies to patients worldwide.
